Telepsychology for Benzodiazepines Withdrawal in Adults Suffering From Hypnotic-dependent Insomnia

Summary

Long-term use of benzodiazepines is a long-standing problem, but the optimal withdrawal modalities are not known. The main objective of this study is to compare the effectiveness of a psychological support versus a psychotherapeutic intervention (Acceptance and Commitment Therapy, ACT) added to a withdrawal program on the reduction of benzodiazepines use in adults suffering from insomnia and hypnotic dependence.

Conditions

• Chronic Insomnia
• Hypnotic Dependence

Interventions

BEHAVIORAL

Medium duration withdrawal programme with ACT

* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks. * 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT.

BEHAVIORAL

Long duration withdrawal programme with ACT

* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks. * 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT.

BEHAVIORAL

Medium duration withdrawal programme without ACT

10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.

BEHAVIORAL

Long duration withdrawal programme without ACT

10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.

Sponsors & Collaborators

• Association Nationale de Promotion des Connaissances sur le Sommeil

  lead OTHER

Principal Investigators

• Benjamin Putois, MD, Ph.D · Lyon Neuroscience Research Centre, CNRS UMR 5292 - INSERM U1028 - Lyon 1 University, France

• Laure Peter-Derex, MD, Ph.D · Lyon Neuroscience Research Centre, CNRS UMR 5292 - INSERM U1028 - Lyon 1 University, France

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-06-03

Primary Completion

2024-08-01

Completion

2025-04-04

Countries

• Switzerland

Study Locations